Continuous intravenous intradialysis versus intravenous postdialysis erythropoietin therapy in chronic haemodialysis patients: a randomized, controlled, crossover study

Background. Subcutaneous recombinant human erythropoietin seems to be more effective than intravenous administration. Local pain, however, may diminish patient compliance with the subcutaneous route. Recently continuous intravenous intradialysis administration of rHuEpo has been reported to be more...

Full description

Saved in:
Bibliographic Details
Published in:Nephrology, dialysis, transplantation dialysis, transplantation, 1998-01, Vol.13 (1), p.89-92
Main Authors: Rocha, Jose L., Gentil, Miguel A., Gili, Miguel, Gil, Luis, Cabello, Virginia, Bernal, Gabriel
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
anaemia
Anemia - therapy
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
chronic kidney failure
continuous intravenous infusion
Cross-Over Studies
crossover study
Erythropoietin - administration & dosage
Female
haemodialysis
Humans
Infusions, Intravenous
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Recombinant Proteins
Renal Dialysis
rHuEpo
route of administration
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. Subcutaneous recombinant human erythropoietin seems to be more effective than intravenous administration. Local pain, however, may diminish patient compliance with the subcutaneous route. Recently continuous intravenous intradialysis administration of rHuEpo has been reported to be more efficacious in stimulating erythropoiesis than the usual postdialysis intravenous bolus. Methods. We conducted a randomized, controlled, crossover study on stable chronic haemodialysis patients to compare the efficacy of continuous intradialysis rHuEpo therapy with intravenous postdialysis administration. Twenty patients were selected and randomly assigned to receive rHuEpo either postdialysis (control phase) or by continuous intradialysis perfusion (slow Epo phase) for 12 weeks. After this period, patients were switched to the alternative method for 12 additional weeks. The erythropoietin dose remained unchanged during the study. Haematocrit was monitored weekly and iron metabolism, serum Epo, and vitamins were measured monthly. Urea kinetics and iPTH measurements were performed every 3 months. Results. Three patients were excluded because of unrelated problems. The final mean haematocrit was unchanged from previous basal values in both phases and no statistical differences were found for any parameter between the groups. No differences were found in iron metabolism nor in urea kinetic parameters. Conclusions. Continuous intravenous intradialysis administration of rHuEpo is not more effective than an intravenous postdialysis bolus as rHuEpo maintenance therapy in stable chronic haemodialysis patients.
ISSN:0931-0509
1460-2385
DOI:10.1093/ndt/13.1.89